Expert Opinion on Drug Delivery-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1101625, encodeId=f151110162550, content=选刊时选择几个比较合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101626, encodeId=23a4110162656, content=如何评估自身文章的IF，或者说如何更好地定位自己的文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842488, encodeId=bcb3842488ea, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17e85414121, createdName=ms7933220824164544, createdTime=Sat Apr 21 10:23:29 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842487, encodeId=5c7384248e62, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2635414011, createdName=ms8782559743879884, createdTime=Sat Apr 21 10:23:21 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842312, encodeId=8cd6842312f4, content=审稿速度:2.0 经验分享：投稿两个月才返回结果，未送审，等待编辑处理花了两个月。该杂志主要是综述文章，不知是不是文章为original research的原因，才花了这么久。但是编辑处理也太慢了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4935414017, createdName=ms7761655755119078, createdTime=Fri Apr 13 09:46:28 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544269, encodeId=d82954426908, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532381, encodeId=2d1453238136, content=你好，我想问expert opinion on drug delivery投稿并成功后，状态为Awaiting Commissioning Editor Processing, 系统发来邮件，并附有PDF，邮件中写着“If you have not already done so, please complete and return the attached disclosure form”.然后说让选择审稿方式，需不需要加速什么的，我需要回复么？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9741690214, createdName=jata, createdTime=Wed Feb 01 15:25:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526661, encodeId=ad0d526661af, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：相当困难，修改了很多次，对研究完善性要求也很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Sep 01 16:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481420, encodeId=5a8448142067, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=481, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2021-12-27 桑晒麦拉

选刊时选择几个比较合适？

50 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1101625, encodeId=f151110162550, content=选刊时选择几个比较合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101626, encodeId=23a4110162656, content=如何评估自身文章的IF，或者说如何更好地定位自己的文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842488, encodeId=bcb3842488ea, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17e85414121, createdName=ms7933220824164544, createdTime=Sat Apr 21 10:23:29 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842487, encodeId=5c7384248e62, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2635414011, createdName=ms8782559743879884, createdTime=Sat Apr 21 10:23:21 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842312, encodeId=8cd6842312f4, content=审稿速度:2.0 经验分享：投稿两个月才返回结果，未送审，等待编辑处理花了两个月。该杂志主要是综述文章，不知是不是文章为original research的原因，才花了这么久。但是编辑处理也太慢了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4935414017, createdName=ms7761655755119078, createdTime=Fri Apr 13 09:46:28 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544269, encodeId=d82954426908, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532381, encodeId=2d1453238136, content=你好，我想问expert opinion on drug delivery投稿并成功后，状态为Awaiting Commissioning Editor Processing, 系统发来邮件，并附有PDF，邮件中写着“If you have not already done so, please complete and return the attached disclosure form”.然后说让选择审稿方式，需不需要加速什么的，我需要回复么？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9741690214, createdName=jata, createdTime=Wed Feb 01 15:25:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526661, encodeId=ad0d526661af, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：相当困难，修改了很多次，对研究完善性要求也很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Sep 01 16:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481420, encodeId=5a8448142067, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=481, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2021-12-27 衣谷

如何评估自身文章的IF，或者说如何更好地定位自己的文章？

63 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1101625, encodeId=f151110162550, content=选刊时选择几个比较合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101626, encodeId=23a4110162656, content=如何评估自身文章的IF，或者说如何更好地定位自己的文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842488, encodeId=bcb3842488ea, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17e85414121, createdName=ms7933220824164544, createdTime=Sat Apr 21 10:23:29 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842487, encodeId=5c7384248e62, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2635414011, createdName=ms8782559743879884, createdTime=Sat Apr 21 10:23:21 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842312, encodeId=8cd6842312f4, content=审稿速度:2.0 经验分享：投稿两个月才返回结果，未送审，等待编辑处理花了两个月。该杂志主要是综述文章，不知是不是文章为original research的原因，才花了这么久。但是编辑处理也太慢了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4935414017, createdName=ms7761655755119078, createdTime=Fri Apr 13 09:46:28 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544269, encodeId=d82954426908, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532381, encodeId=2d1453238136, content=你好，我想问expert opinion on drug delivery投稿并成功后，状态为Awaiting Commissioning Editor Processing, 系统发来邮件，并附有PDF，邮件中写着“If you have not already done so, please complete and return the attached disclosure form”.然后说让选择审稿方式，需不需要加速什么的，我需要回复么？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9741690214, createdName=jata, createdTime=Wed Feb 01 15:25:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526661, encodeId=ad0d526661af, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：相当困难，修改了很多次，对研究完善性要求也很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Sep 01 16:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481420, encodeId=5a8448142067, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=481, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2018-04-21 ms7933220824164544

审稿速度:4.0
经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery

114 0

[GetPortalCommentsPageByObjectIdResponse(id=1101625, encodeId=f151110162550, content=选刊时选择几个比较合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101626, encodeId=23a4110162656, content=如何评估自身文章的IF，或者说如何更好地定位自己的文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842488, encodeId=bcb3842488ea, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17e85414121, createdName=ms7933220824164544, createdTime=Sat Apr 21 10:23:29 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842487, encodeId=5c7384248e62, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2635414011, createdName=ms8782559743879884, createdTime=Sat Apr 21 10:23:21 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842312, encodeId=8cd6842312f4, content=审稿速度:2.0 经验分享：投稿两个月才返回结果，未送审，等待编辑处理花了两个月。该杂志主要是综述文章，不知是不是文章为original research的原因，才花了这么久。但是编辑处理也太慢了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4935414017, createdName=ms7761655755119078, createdTime=Fri Apr 13 09:46:28 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544269, encodeId=d82954426908, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532381, encodeId=2d1453238136, content=你好，我想问expert opinion on drug delivery投稿并成功后，状态为Awaiting Commissioning Editor Processing, 系统发来邮件，并附有PDF，邮件中写着“If you have not already done so, please complete and return the attached disclosure form”.然后说让选择审稿方式，需不需要加速什么的，我需要回复么？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9741690214, createdName=jata, createdTime=Wed Feb 01 15:25:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526661, encodeId=ad0d526661af, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：相当困难，修改了很多次，对研究完善性要求也很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Sep 01 16:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481420, encodeId=5a8448142067, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=481, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2018-04-21 ms8782559743879884

审稿速度:4.0
经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery

131 0

[GetPortalCommentsPageByObjectIdResponse(id=1101625, encodeId=f151110162550, content=选刊时选择几个比较合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101626, encodeId=23a4110162656, content=如何评估自身文章的IF，或者说如何更好地定位自己的文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842488, encodeId=bcb3842488ea, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17e85414121, createdName=ms7933220824164544, createdTime=Sat Apr 21 10:23:29 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842487, encodeId=5c7384248e62, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2635414011, createdName=ms8782559743879884, createdTime=Sat Apr 21 10:23:21 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842312, encodeId=8cd6842312f4, content=审稿速度:2.0 经验分享：投稿两个月才返回结果，未送审，等待编辑处理花了两个月。该杂志主要是综述文章，不知是不是文章为original research的原因，才花了这么久。但是编辑处理也太慢了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4935414017, createdName=ms7761655755119078, createdTime=Fri Apr 13 09:46:28 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544269, encodeId=d82954426908, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532381, encodeId=2d1453238136, content=你好，我想问expert opinion on drug delivery投稿并成功后，状态为Awaiting Commissioning Editor Processing, 系统发来邮件，并附有PDF，邮件中写着“If you have not already done so, please complete and return the attached disclosure form”.然后说让选择审稿方式，需不需要加速什么的，我需要回复么？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9741690214, createdName=jata, createdTime=Wed Feb 01 15:25:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526661, encodeId=ad0d526661af, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：相当困难，修改了很多次，对研究完善性要求也很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Sep 01 16:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481420, encodeId=5a8448142067, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=481, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2018-04-13 ms7761655755119078

审稿速度:2.0
经验分享：投稿两个月才返回结果，未送审，等待编辑处理花了两个月。该杂志主要是综述文章，不知是不是文章为original research的原因，才花了这么久。但是编辑处理也太慢了。

118 0

[GetPortalCommentsPageByObjectIdResponse(id=1101625, encodeId=f151110162550, content=选刊时选择几个比较合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101626, encodeId=23a4110162656, content=如何评估自身文章的IF，或者说如何更好地定位自己的文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842488, encodeId=bcb3842488ea, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17e85414121, createdName=ms7933220824164544, createdTime=Sat Apr 21 10:23:29 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842487, encodeId=5c7384248e62, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2635414011, createdName=ms8782559743879884, createdTime=Sat Apr 21 10:23:21 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842312, encodeId=8cd6842312f4, content=审稿速度:2.0 经验分享：投稿两个月才返回结果，未送审，等待编辑处理花了两个月。该杂志主要是综述文章，不知是不是文章为original research的原因，才花了这么久。但是编辑处理也太慢了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4935414017, createdName=ms7761655755119078, createdTime=Fri Apr 13 09:46:28 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544269, encodeId=d82954426908, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532381, encodeId=2d1453238136, content=你好，我想问expert opinion on drug delivery投稿并成功后，状态为Awaiting Commissioning Editor Processing, 系统发来邮件，并附有PDF，邮件中写着“If you have not already done so, please complete and return the attached disclosure form”.然后说让选择审稿方式，需不需要加速什么的，我需要回复么？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9741690214, createdName=jata, createdTime=Wed Feb 01 15:25:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526661, encodeId=ad0d526661af, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：相当困难，修改了很多次，对研究完善性要求也很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Sep 01 16:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481420, encodeId=5a8448142067, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=481, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2017-07-16 zheyang

还是5分多,虽然没有大变化,能稳定在些,也算是中上等

364 0

[GetPortalCommentsPageByObjectIdResponse(id=1101625, encodeId=f151110162550, content=选刊时选择几个比较合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101626, encodeId=23a4110162656, content=如何评估自身文章的IF，或者说如何更好地定位自己的文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842488, encodeId=bcb3842488ea, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17e85414121, createdName=ms7933220824164544, createdTime=Sat Apr 21 10:23:29 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842487, encodeId=5c7384248e62, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2635414011, createdName=ms8782559743879884, createdTime=Sat Apr 21 10:23:21 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842312, encodeId=8cd6842312f4, content=审稿速度:2.0 经验分享：投稿两个月才返回结果，未送审，等待编辑处理花了两个月。该杂志主要是综述文章，不知是不是文章为original research的原因，才花了这么久。但是编辑处理也太慢了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4935414017, createdName=ms7761655755119078, createdTime=Fri Apr 13 09:46:28 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544269, encodeId=d82954426908, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532381, encodeId=2d1453238136, content=你好，我想问expert opinion on drug delivery投稿并成功后，状态为Awaiting Commissioning Editor Processing, 系统发来邮件，并附有PDF，邮件中写着“If you have not already done so, please complete and return the attached disclosure form”.然后说让选择审稿方式，需不需要加速什么的，我需要回复么？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9741690214, createdName=jata, createdTime=Wed Feb 01 15:25:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526661, encodeId=ad0d526661af, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：相当困难，修改了很多次，对研究完善性要求也很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Sep 01 16:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481420, encodeId=5a8448142067, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=481, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2017-02-01 jata

你好，我想问expert opinion on drug delivery投稿并成功后，状态为Awaiting Commissioning Editor Processing, 系统发来邮件，并附有PDF，邮件中写着“If you have not already done so, please complete and return the attached disclosure form”.然后说让选择审稿方式，需不需要加速什么的，我需要回复么？

302 0

[GetPortalCommentsPageByObjectIdResponse(id=1101625, encodeId=f151110162550, content=选刊时选择几个比较合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101626, encodeId=23a4110162656, content=如何评估自身文章的IF，或者说如何更好地定位自己的文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842488, encodeId=bcb3842488ea, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17e85414121, createdName=ms7933220824164544, createdTime=Sat Apr 21 10:23:29 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842487, encodeId=5c7384248e62, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2635414011, createdName=ms8782559743879884, createdTime=Sat Apr 21 10:23:21 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842312, encodeId=8cd6842312f4, content=审稿速度:2.0 经验分享：投稿两个月才返回结果，未送审，等待编辑处理花了两个月。该杂志主要是综述文章，不知是不是文章为original research的原因，才花了这么久。但是编辑处理也太慢了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4935414017, createdName=ms7761655755119078, createdTime=Fri Apr 13 09:46:28 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544269, encodeId=d82954426908, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532381, encodeId=2d1453238136, content=你好，我想问expert opinion on drug delivery投稿并成功后，状态为Awaiting Commissioning Editor Processing, 系统发来邮件，并附有PDF，邮件中写着“If you have not already done so, please complete and return the attached disclosure form”.然后说让选择审稿方式，需不需要加速什么的，我需要回复么？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9741690214, createdName=jata, createdTime=Wed Feb 01 15:25:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526661, encodeId=ad0d526661af, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：相当困难，修改了很多次，对研究完善性要求也很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Sep 01 16:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481420, encodeId=5a8448142067, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=481, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2016-09-01 lovetcm

审稿速度:3.0 | 投稿命中率:50.0
经验分享：相当困难，修改了很多次，对研究完善性要求也很高

299 0

[GetPortalCommentsPageByObjectIdResponse(id=1101625, encodeId=f151110162550, content=选刊时选择几个比较合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101626, encodeId=23a4110162656, content=如何评估自身文章的IF，或者说如何更好地定位自己的文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842488, encodeId=bcb3842488ea, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17e85414121, createdName=ms7933220824164544, createdTime=Sat Apr 21 10:23:29 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842487, encodeId=5c7384248e62, content=审稿速度:4.0 经验分享：编辑回复的网址打不开，怎么办expert opinion on drug delivery , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2635414011, createdName=ms8782559743879884, createdTime=Sat Apr 21 10:23:21 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=842312, encodeId=8cd6842312f4, content=审稿速度:2.0 经验分享：投稿两个月才返回结果，未送审，等待编辑处理花了两个月。该杂志主要是综述文章，不知是不是文章为original research的原因，才花了这么久。但是编辑处理也太慢了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4935414017, createdName=ms7761655755119078, createdTime=Fri Apr 13 09:46:28 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544269, encodeId=d82954426908, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532381, encodeId=2d1453238136, content=你好，我想问expert opinion on drug delivery投稿并成功后，状态为Awaiting Commissioning Editor Processing, 系统发来邮件，并附有PDF，邮件中写着“If you have not already done so, please complete and return the attached disclosure form”.然后说让选择审稿方式，需不需要加速什么的，我需要回复么？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9741690214, createdName=jata, createdTime=Wed Feb 01 15:25:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526661, encodeId=ad0d526661af, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：相当困难，修改了很多次，对研究完善性要求也很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Sep 01 16:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481420, encodeId=5a8448142067, content=看涨哦，明年会不会再涨？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=481, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:51:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2011-06-29 medwu

看涨哦，明年会不会再涨？

481 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务